Phase II Study on Weekly Bolus Topotecan in Advanced or Recurrent Cervical Cancer

Oncology ◽  
2011 ◽  
Vol 80 (5-6) ◽  
pp. 390-394 ◽  
Author(s):  
D. Lorusso ◽  
S. Mainenti ◽  
A. Pietragalla ◽  
E. Fusco ◽  
P. Malaguti ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Cervical Cancer ◽  
Weekly Bolus

scholarly journals ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer

2014 ◽  
Vol 2 (S3) ◽  
Author(s):  
Robert G Petit ◽  
Ajay Mehta ◽  
Minish Jain ◽  
Sudeep Gupta ◽  
Rajnish Nagarkar ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Indian Women ◽  
Recurrent Cervical Cancer ◽  
Hpv E7

A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy

2019 ◽  
Vol 29 (3) ◽  
pp. 474-479
Author(s):  
Seiji Mabuchi ◽  
Eriko Yokoi ◽  
Kotaro Shimura ◽  
Naoko Komura ◽  
Yuri Matsumoto ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Response Rate ◽  
Phase Ii Study ◽  
Progression Free Survival ◽  
Recurrent Cervical Cancer ◽  
Free Survival ◽  
Platinum Based Chemotherapy ◽  
Previously Treated ◽  
Grade 3

ObjectivesWe conducted a phase II study to investigate the efficacy and toxicities of irinotecan plus oral S-1 in patients with advanced or recurrent uterine cervical cancer.MethodsPatients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy were enrolled. Irinotecan (150 mg/m2) was administered intravenously over the course of 90 min on day 1, and S-1 (80 mg/m2) was given orally in two divided doses from days 1 to 14 of a 21 day cycle. The primary endpoint of this phase II study was response rate. Secondary endpoints included safety, progression free survival, and overall survival.ResultsA total of 19 patients were enrolled and treated. The response rate was 29.4%. Grade 3–4 hematologic toxicities were observed in three patients (15.7%). The only grade 3–4 non-hematologic toxicity observed was grade 3 diarrhea. The median progression free survival and overall survival were 3 months and 9 months, respectively.ConclusionS-1 plus irinotecan in a 3 weekly setting is safe and active in women with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy. Future corroborative clinical studies are warranted.

Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5515-5515 ◽  
Author(s):  
G. Ferrandina ◽  
D. Lorusso ◽  
M. Ludovisi ◽  
S. Pignata ◽  
R. Sorio ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Cervical Cancer

Phase II study of S-1 in patients with advanced or recurrent cervical cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5514-5514 ◽  
Author(s):  
Y. Hirai ◽  
N. Katsumata ◽  
S. Kamiura ◽  
T. Sugiyama ◽  
K. Kokawa ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Cervical Cancer

scholarly journals A Phase II Study of 5-Fluorouracil/Cisplatinum in Recurrent Cervical Cancer

1990 ◽  
Vol 29 (1) ◽  
pp. 25-28 ◽  
Author(s):  
J. Kærn ◽  
C. Tropé ◽  
V. Abeler ◽  
T. Iversen ◽  
K. Kjørstad
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Cervical Cancer

Phase II Study of Irinotecan and Cisplatin as First-Line Chemotherapy in Advanced or Recurrent Cervical Cancer

Oncology ◽  
2000 ◽  
Vol 58 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Toru Sugiyama ◽  
Michiaki Yakushiji ◽  
Kiichiro Noda ◽  
Masanori Ikeda ◽  
Ryouichi Kudoh ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
First Line ◽  
Recurrent Cervical Cancer ◽  
Line Chemotherapy

Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer

2006 ◽  
Vol 16 (3) ◽  
pp. 1165-1171 ◽  
Author(s):  
F.C. MALUF ◽  
A.L. LEISER ◽  
C. AGHAJANIAN ◽  
P. SABBATINI ◽  
S. PEZZULLI ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Cervical Cancer
Sign in / Sign up

Export Citation Format

Share Document